Sanofi (NASDAQ:SNY) Shares Sold by NewSquare Capital LLC

NewSquare Capital LLC lowered its holdings in shares of Sanofi (NASDAQ:SNY) by 0.8% in the fourth quarter, Holdings Channel reports. The firm owned 111,100 shares of the company’s stock after selling 940 shares during the quarter. NewSquare Capital LLC’s holdings in Sanofi were worth $5,293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of SNY. Jennison Associates LLC grew its stake in shares of Sanofi by 938.0% in the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after purchasing an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after buying an additional 1,424,289 shares during the period. DAVENPORT & Co LLC raised its position in Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after buying an additional 664,455 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Up 2.1 %

Shares of SNY stock opened at $57.70 on Wednesday. The stock has a market cap of $146.43 billion, a P/E ratio of 23.17, a P/E/G ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The business has a fifty day simple moving average of $52.00 and a 200-day simple moving average of $52.64.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on SNY shares. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.